AGENUS INC (AGEN)

US00847G8042 - Common Stock

17.53  -0.17 (-0.96%)

Fundamental Rating

2

Overall AGEN gets a fundamental rating of 2 out of 10. We evaluated AGEN against 574 industry peers in the Biotechnology industry. Both the profitability and financial health of AGEN have multiple concerns. AGEN is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.
In the past year AGEN has reported a negative cash flow from operations.
In the past 5 years AGEN always reported negative net income.
AGEN had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -93.39%, AGEN is not doing good in the industry: 75.66% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -93.39%
ROE N/A
ROIC N/A
ROA(3y)-45.6%
ROA(5y)-58.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

AGEN has a better Gross Margin (99.43%) than 98.95% of its industry peers.
In the last couple of years the Gross Margin of AGEN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.23%
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGEN has been increased compared to 1 year ago.
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
The debt/assets ratio for AGEN is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -12.59, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
AGEN has a worse Altman-Z score (-12.59) than 82.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.59
ROIC/WACCN/A
WACC10.84%

2.3 Liquidity

A Current Ratio of 0.24 indicates that AGEN may have some problems paying its short term obligations.
AGEN has a worse Current ratio (0.24) than 97.37% of its industry peers.
A Quick Ratio of 0.24 indicates that AGEN may have some problems paying its short term obligations.
The Quick ratio of AGEN (0.24) is worse than 96.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.24

6

3. Growth

3.1 Past

AGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1465.85%.
AGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 69.94%.
The Revenue has been growing by 33.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1465.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1281.82%
Revenue 1Y (TTM)69.94%
Revenue growth 3Y21.03%
Revenue growth 5Y33.56%
Sales Q2Q%22.28%

3.2 Future

Based on estimates for the next years, AGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.62% on average per year.
The Revenue is expected to grow by 29.74% on average over the next years. This is a very strong growth
EPS Next Y9.35%
EPS Next 2Y4.86%
EPS Next 3Y8.47%
EPS Next 5Y10.62%
Revenue Next Year85.27%
Revenue Next 2Y27.01%
Revenue Next 3Y27.74%
Revenue Next 5Y29.74%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

0

4. Valuation

4.1 Price/Earnings Ratio

AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.86%
EPS Next 3Y8.47%

0

5. Dividend

5.1 Amount

No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield N/A

AGENUS INC

NASDAQ:AGEN (7/17/2024, 12:56:24 PM)

17.53

-0.17 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap368.13M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.39%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 99.43%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.24
Quick Ratio 0.24
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1465.85%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y9.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)69.94%
Revenue growth 3Y21.03%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y